Alpha Tau Makes History with First Lung Cancer Treatment
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), renowned for its innovative alpha-radiation cancer therapy known as Alpha DaRT, has taken a huge step forward by treating its first patient with recurrent lung cancer in a clinical trial. This pivotal event occurred at Hadassah Medical Center and represents a significant milestone in the fight against this challenging disease.
Details of the Clinical Trial
The current clinical trial aims to treat up to ten patients suffering from recurrent tumors situated in the mediastinum area of the chest. The study is designed to assess the safety and feasibility of delivering Alpha DaRT sources into the lungs through an endobronchial ultrasound (EBUS) procedure. In particular, it will monitor the successful placement of sources and track any potential adverse events related to the treatment. Furthermore, the trial will evaluate the effectiveness of Alpha DaRT, investigating tumor responses after one and three months following treatment, using RECIST criteria to measure tumor coverage.
WHO Statistics on Lung Cancer
Lung cancer remains the leading cause of cancer-related fatalities across the globe, with nearly 2.5 million new cases diagnosed annually, according to the WHO’s International Agency for Research on Cancer. It is frequently identified at advanced stages, which greatly limits treatment options. In the United States, lung cancer ranks as the third most common cancer, with approximately 210,000 new cases reported each year, according to the CDC.
Alpha Tau's Vision for the Future
CEO Uzi Sofer emphasized the company's commitment to expanding the application of Alpha DaRT to a wider range of indications, especially for complex tumors formed within visceral organs. “Given the widespread nature of lung cancer, initiating treatment for such a significant condition is vital,” said Sofer. His comments reflect the growing interest within the medical community for using Alpha DaRT across multiple cancer types.
Excitement from Medical Professionals
Prof. Neville Berkman, the principal investigator of the study and the Director of the Institute of Pulmonology at Hadassah Medical Center, expressed enthusiasm about employing this cutting-edge technology for treating lung cancer patients. The utilization of EBUS in this context allows for the precise insertion of Alpha DaRT sources, marking a significant development in cancer treatment methodologies.
The Promise of Alpha DaRT Therapy
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to deliver potent alpha-irradiation effect to solid tumors through a direct approach. Through the controlled release of radium-224, this treatment aims to primarily impact tumor cells while minimizing harm to surrounding healthy tissues. This focused approach is particularly crucial for organs like the lungs, where proximity to critical structures raises potential risks associated with traditional therapies.
Potential Impact on the Cancer Community
Dr. Robert Den, Chief Medical Officer of Alpha Tau, noted, “This moment is pivotal as we explore Alpha DaRT's application to the lungs, possibly unlocking new treatment avenues for patients facing limited options.” Treatments in this area could help bridge the gap for those who have undergone multiple therapies without significant success, highlighting the evolving landscape of cancer treatment options.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau Medical specializes in developing innovative cancer therapeutics, with a focus on utilizing the Alpha DaRT technology to tackle solid tumors. Conceived by prominent researchers from Tel Aviv University, this therapy is at the forefront of oncological research and development.
Frequently Asked Questions
What is Alpha DaRT?
Alpha DaRT is a cutting-edge radiation therapy focused on treating solid tumors by delivering alpha-emitting particles directly at the cancer cells, minimizing damage to healthy tissues.
What recent milestones has Alpha Tau achieved?
Alpha Tau recently treated its first lung cancer patient using Alpha DaRT, marking a significant advancement in their clinical development and commitment to innovative cancer treatments.
How does lung cancer rank among other cancers?
Lung cancer is the leading cause of cancer-related deaths globally and ranks as the third most common cancer in the United States, underscoring its severity and the need for effective treatments.
What are the objectives of the recent clinical trial?
The clinical trial aims to assess the safety, feasibility, and efficacy of Alpha DaRT in treating patients with recurrent lung tumors, potentially paving the way for broader applications in cancer therapy.
Who leads the clinical trial at Hadassah Medical Center?
Prof. Neville Berkman is the principal investigator overseeing the clinical trial at Hadassah Medical Center, highlighting the hospital's commitment to advancing cancer treatment methodologies.
